Aclaris Therapts (ACRS)

$1.40 -0.04 (-2.78%)
Market Cap 159.17M
Revenue (ttm) 18.72M
Net Income (ttm) -132.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -705.50%
Debt to Equity Ratio 0.00
Volume 517,230
Avg Vol 777,458
Day's Range N/A - N/A
Shares Out 108.28M
Stochastic %K 0%
Beta 0.41
Analysts Strong Sell
Price Target $8.14

Company Profile

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its Contract Research segment provides laboratory services. The company also develops ATI-1777, a soft JA...

Industry: Biotechnology
Sector: Healthcare
Phone: 484 324 7933
Address:
701 Lee Road, Suite 103, Wayne, United States
OriginalTradeonrumor
OriginalTradeonrumor Jun. 16 at 7:14 PM
$ACRS I’m in!! Now let’s get that news out!
1 · Reply
Bionco
Bionco Jun. 16 at 3:55 PM
$ACRS CTTQ, our partner in China, will release Phase 2b trial data for ATI-045 in Severe Asthma and Chronic Rhinosinusitis in June. Based on partial data we shared: ATI-045 successfully targets TSLP as designed, demonstrates enhanced efficacy, and also shows a favorable safety profile. Phase 3 trials for both indications are already underway. They are also conducting a phase 2 trial in COPD. We are seeking partners to develop ATI-045 for respiratory indications for ex-Great China market!
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Jun. 16 at 2:44 PM
$ACRS been nibbling today here …rolling the dice on imminent news being positive Goal is about 30k shares and more than half way there now Let’s see what happens!
0 · Reply
buymoremakemore
buymoremakemore Jun. 16 at 2:01 PM
$ACRS 15k at @$1.5. Hidden gem 💎
0 · Reply
buymoremakemore
buymoremakemore Jun. 16 at 5:15 AM
$ACRS Hopefully data not released in middle of night. Will wake up early to get in
0 · Reply
buymoremakemore
buymoremakemore Jun. 15 at 8:14 PM
$ACRS Gonna buy 10k shares in morning
0 · Reply
Bionco
Bionco Jun. 12 at 10:18 AM
$ACRS ATI-2138 data is imminent(any day )! We see no reason it would be inferior to CPI-818. ATI-2138 is 15-38x more potent than CPI-818 in inhibiting the ITK enzyme activity and 100x more potent than CPI-818 in blocking the Th2 derived cytokines, IL4, IL-5 and IL-13.
2 · Reply
Bionco
Bionco Jun. 11 at 8:07 PM
$ACRS avged up and scooped up some at the lowest of today
0 · Reply
Bionco
Bionco Jun. 10 at 7:59 PM
$ACRS slapped the ask!
0 · Reply
imjustjimmymoore
imjustjimmymoore Jun. 10 at 12:01 PM
$ACRS JUST LOADED UP LETS GO! GLTA
0 · Reply
Latest News on ACRS
Aclaris Therapeutics to Participate in Two June Healthcare Conferences

May 28, 2025, 9:20 AM EDT - 20 days ago

Aclaris Therapeutics to Participate in Two June Healthcare Conferences

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

May 9, 2025, 7:00 AM EDT - 5 weeks ago

Aclaris Therapeutics to Participate in the HC Wainwright “HCW@Home” Series

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 6:50 AM EDT - 5 weeks ago

Aclaris Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Apr 29, 2025, 7:00 AM EDT - 7 weeks ago

Aclaris Therapeutics Appoints Jesse Hall, M.D. as Chief Medical Officer

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

Mar 4, 2025, 7:00 AM EST - 3 months ago

Aclaris Therapeutics to Participate in Two March Healthcare Conferences

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Feb 12, 2025, 6:50 AM EST - 4 months ago

New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Jan 30, 2025, 4:01 PM EST - 4 months ago

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Jan 6, 2025, 4:30 PM EST - 5 months ago

Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Dec 23, 2024, 1:41 PM EST - 6 months ago

Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:30 PM EST - 7 months ago

Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Nov 19, 2024, 3:27 PM EST - 7 months ago

Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Nov 18, 2024, 8:50 AM EST - 7 months ago

Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Nov 18, 2024, 8:10 AM EST - 7 months ago

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline

Aclaris Therapeutics Announces $80 Million Private Placement

Nov 18, 2024, 8:10 AM EST - 7 months ago

Aclaris Therapeutics Announces $80 Million Private Placement

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Sep 17, 2024, 7:00 AM EDT - 9 months ago

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Sep 10, 2024, 7:00 AM EDT - 10 months ago

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Jul 16, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Jun 25, 2024, 12:36 PM EDT - 1 year ago

Rheumatoid Arthritis Market and Epidemiology Forecast 2024-2034 Featuring Analysis of ATI-450 (Aclaris Therapeutics) and Olumiant/Baricitinib (Eli Lilly/Incyte)

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Jun 6, 2024, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

American Clinical Research Services Announces Strategic Acquisition of Elixia

May 8, 2024, 6:30 AM EDT - 1 year ago

American Clinical Research Services Announces Strategic Acquisition of Elixia

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

May 7, 2024, 9:44 PM EDT - 1 year ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2024 Earnings Call Transcript

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 7, 2024, 4:01 PM EDT - 1 year ago

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Feb 27, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Jan 10, 2024, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

Aclaris Therapeutics Provides Corporate Update

Dec 19, 2023, 4:01 PM EST - 1 year ago

Aclaris Therapeutics Provides Corporate Update

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Dec 5, 2023, 4:01 PM EST - 1 year ago

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

Nov 13, 2023, 7:19 AM EST - 1 year ago

Aclaris Therapeutics to stop development of rheumatoid arthritis drug

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Nov 13, 2023, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Nov 6, 2023, 7:00 AM EST - 1 year ago

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Oct 3, 2023, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

Sep 28, 2023, 7:18 AM EDT - 1 year ago

Aclaris Therapeutics: The Many Lives Of This Biopharmaceutical Developer

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Sep 20, 2023, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

Sep 18, 2023, 7:00 AM EDT - 1 year ago

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Aug 7, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch

Jul 11, 2023, 7:31 PM EDT - 2 years ago

Aclaris Therapeutics: Q4 Of 2023 Catalyst Makes This A Must Watch

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

Jun 13, 2023, 7:01 AM EDT - 2 years ago

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

Jun 2, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

Aclaris Therapeutics, Inc. (ACRS) Q1 2023 Earnings Call Transcript

May 8, 2023, 11:56 AM EDT - 2 years ago

Aclaris Therapeutics, Inc. (ACRS) Q1 2023 Earnings Call Transcript

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

May 8, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

May 2, 2023, 7:01 AM EDT - 2 years ago

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Mar 27, 2023, 7:00 AM EDT - 2 years ago

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

Aclaris Therapeutics: Potential Speculative Play After Zunsemetinib Misses Mark On Hidradenitis Suppurativa

Mar 9, 2023, 7:30 AM EST - 2 years ago

Aclaris Therapeutics: Potential Speculative Play After Zunsemetinib Misses Mark On Hidradenitis Suppurativa

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Feb 23, 2023, 7:00 AM EST - 2 years ago

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference

Feb 9, 2023, 4:01 PM EST - 2 years ago

Aclaris Therapeutics to Participate in the Virtual SVB Securities Global Biopharma Conference

Aclaris Therapeutics Has Strong Upside Potential, But Shares Could Be Lower

Jan 10, 2023, 4:04 PM EST - 2 years ago

Aclaris Therapeutics Has Strong Upside Potential, But Shares Could Be Lower

Aclaris Therapeutics Provides 2023 Outlook

Jan 6, 2023, 7:01 AM EST - 2 years ago

Aclaris Therapeutics Provides 2023 Outlook

Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

Nov 29, 2022, 7:00 AM EST - 2 years ago

Aclaris Therapeutics and Pediatrix Therapeutics Announce License Agreement for ATI-1777 in Greater China

Aclaris Therapeutics Announces Key Leadership Transitions

Nov 22, 2022, 4:01 PM EST - 2 years ago

Aclaris Therapeutics Announces Key Leadership Transitions

Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences

Nov 10, 2022, 4:01 PM EST - 2 years ago

Aclaris Therapeutics to Participate in Two November Healthcare Investor Conferences

OriginalTradeonrumor
OriginalTradeonrumor Jun. 16 at 7:14 PM
$ACRS I’m in!! Now let’s get that news out!
1 · Reply
Bionco
Bionco Jun. 16 at 3:55 PM
$ACRS CTTQ, our partner in China, will release Phase 2b trial data for ATI-045 in Severe Asthma and Chronic Rhinosinusitis in June. Based on partial data we shared: ATI-045 successfully targets TSLP as designed, demonstrates enhanced efficacy, and also shows a favorable safety profile. Phase 3 trials for both indications are already underway. They are also conducting a phase 2 trial in COPD. We are seeking partners to develop ATI-045 for respiratory indications for ex-Great China market!
0 · Reply
OriginalTradeonrumor
OriginalTradeonrumor Jun. 16 at 2:44 PM
$ACRS been nibbling today here …rolling the dice on imminent news being positive Goal is about 30k shares and more than half way there now Let’s see what happens!
0 · Reply
buymoremakemore
buymoremakemore Jun. 16 at 2:01 PM
$ACRS 15k at @$1.5. Hidden gem 💎
0 · Reply
buymoremakemore
buymoremakemore Jun. 16 at 5:15 AM
$ACRS Hopefully data not released in middle of night. Will wake up early to get in
0 · Reply
buymoremakemore
buymoremakemore Jun. 15 at 8:14 PM
$ACRS Gonna buy 10k shares in morning
0 · Reply
Bionco
Bionco Jun. 12 at 10:18 AM
$ACRS ATI-2138 data is imminent(any day )! We see no reason it would be inferior to CPI-818. ATI-2138 is 15-38x more potent than CPI-818 in inhibiting the ITK enzyme activity and 100x more potent than CPI-818 in blocking the Th2 derived cytokines, IL4, IL-5 and IL-13.
2 · Reply
Bionco
Bionco Jun. 11 at 8:07 PM
$ACRS avged up and scooped up some at the lowest of today
0 · Reply
Bionco
Bionco Jun. 10 at 7:59 PM
$ACRS slapped the ask!
0 · Reply
imjustjimmymoore
imjustjimmymoore Jun. 10 at 12:01 PM
$ACRS JUST LOADED UP LETS GO! GLTA
0 · Reply
hooda
hooda Jun. 9 at 11:20 PM
$ACRS woo woo HC Wainwright analyst reiterated BUY rating with price target of $16 But I bet it goes higher. Too many insiders buying
0 · Reply
Bionco
Bionco Jun. 6 at 4:28 PM
$ACRS head fake again 😠
0 · Reply
Bionco
Bionco Jun. 5 at 10:41 AM
$ACRS most importantly, two ATI-045 phase 2 trials(in China) for respiratory indications met its primary endpoints and has advanced to phase 3 trials ATI-045 phase 1 trial for Ad( in the US) showed unbelievable efficacy with favorable safety profile. Tslp is a clinically validated target. ATI-045 is almost derisked!
0 · Reply
Bionco
Bionco Jun. 5 at 10:31 AM
$ACRS Cash runway extends into the year 2028 ATI-2138 data this month Phase 2b trial of ATI-045 in AD data expected in 2H of 2026 Phase 1a trial of ATI-052 data expected late this year Next G ITK inhibitor IND expected next year. The company will continue to monetize its IP. They are seeking partners in the US to develop ATI-045 for respiratory indications, which could further strengthen the company's balance sheet .
0 · Reply
RollingStockChallenge
RollingStockChallenge Jun. 4 at 9:01 PM
$ACRS jees, break out those rocket emojis
0 · Reply
Bionco
Bionco Jun. 4 at 3:40 PM
$ACRS it is time for us🙌
0 · Reply
RollingStockChallenge
RollingStockChallenge Jun. 4 at 3:24 PM
$ACRS it was $5 within the last 12 months…..no reason for it to be half that price, let alone a quarter which is where we were 2 weeks ago.
0 · Reply
PepCF
PepCF Jun. 4 at 3:11 PM
$ACRS i knew
0 · Reply
RollingStockChallenge
RollingStockChallenge Jun. 4 at 2:46 PM
$ACRS seems like a breakout from levels it’s been stuck at for a while
0 · Reply
Bionco
Bionco Jun. 2 at 2:32 PM
$ACRS avged up today
0 · Reply
Bionco
Bionco Jun. 2 at 12:09 PM
$ACRS why has the company not registered its trial on clinicaltrials.gov?
0 · Reply
DonCorleone77
DonCorleone77 Jun. 2 at 11:15 AM
$ACRS Aclaris Therapeutics initiates Phase 2 trial of bosakitug Aclaris Therapeutics announced that it has initiated a randomized, double-blind, placebo-controlled Phase 2 trial of bosakitug in patients with moderate-to-severe atopic dermatitis. Top line results are expected in the second half of 2026.
1 · Reply